

A1C-2

Tina-quant Hemoglobin A1c Gen.2



Order information

| REF | CONTENT | Analyzer(s) on which cobas c pack(s) can be used |
|--------------|---|---|
| 04528123 190 | Tina-quant Hemoglobin A1c Gen.2 (150 tests) | System-ID 07 6850 2 |
| 04528417 190 | C.f.a.s. HbA1c (3 × 2 mL) | Code 674 |
| 20764833 322 | HbA1c Control N (4 × 0.5 mL) | Code 357 |
| 20764841 322 | HbA1c Control P (4 × 0.5 mL) | Code 358 |
| 05479207 190 | PreciControl HbA1c norm (4 × 1 mL) | Code 208 |
| 05912504 190 | PreciControl HbA1c path (4 × 1 mL) | Code 209 |
| 04528182 190 | Hemolyzing Reagent Gen.2 (51 mL)* | System-ID 07 6873 1 |
| 11488457 122 | HbA1c Hemolyzing Reagent for Tina-quant HbA1c (1000 mL) | For Hemolysate Application only |

* The value encoded in the instrument settings is 45 mL to account for the dead volume of the bottles.

English

System information

Whole Blood Application - Standardized according to IFCC transferable to DCCT/NGSP

| | | |
|---------------|---------|---|
| HB-W2: | ACN 870 | Hemoglobin (Hb) |
| A1-W2: | ACN 880 | Hemoglobin A1c (HbA1c) |
| RW12: | ACN 890 | Ratio (% HbA1c IFCC; not recommended for patient reporting) |
| A1CD2: | ACN 952 | Hemolyzing reagent |

Hemolysate Application - Standardized according to IFCC transferable to DCCT/NGSP

| | | |
|---------------|---------|---|
| HB-H2: | ACN 840 | Hemoglobin (Hb) |
| A1-H2: | ACN 850 | Hemoglobin A1c (HbA1c) |
| RH12: | ACN 860 | Ratio (% HbA1c IFCC; not recommended for patient reporting) |
| A1CD2: | ACN 952 | Hemolyzing reagent |

Intended use

In vitro test for the quantitative determination of mmol/mol hemoglobin A1c (IFCC) and % hemoglobin A1c (DCCT/NGSP) in whole blood or hemolysate on Roche/Hitachi **cobas c** systems. HbA1c determinations are useful for monitoring of long-term blood glucose control in individuals with diabetes mellitus. Moreover, this test is to be used as an aid in diagnosis of diabetes and identifying patients who may be at risk for developing diabetes.

Summary^{1,2,3,4,5,6,7,8,9}

Hemoglobin (Hb) consists of four protein subunits, each containing a heme moiety, and is the red-pigmented protein located in the erythrocytes. Its main function is to transport oxygen and carbon dioxide in blood. Each Hb molecule is able to bind four oxygen molecules. Hb consists of a variety of subfractions and derivatives. Among this heterogeneous group of hemoglobins HbA1c is one of the glycosylated hemoglobins, a subfraction formed by the attachment of various sugars to the Hb molecule. HbA1c is formed in two steps by the nonenzymatic reaction of glucose with the N-terminal amino group of the β-chain of normal adult Hb (HbA). The first step is reversible and yields labile HbA1c. This is rearranged to form stable HbA1c in a second reaction step.

In the erythrocytes, the relative amount of HbA converted to stable HbA1c increases with the average concentration of glucose in the blood. The conversion to stable HbA1c is limited by the erythrocyte's life span of approximately 100 to 120 days. As a result, HbA1c reflects the average blood glucose level during the preceding 2 to 3 months. HbA1c is thus suitable to monitor long-term blood glucose control in individuals with diabetes mellitus. Glucose levels closer to the time of the assay have a greater influence on the HbA1c level.¹

The approximate relationship between HbA1c and mean blood glucose values during the preceding 2 to 3 months was analyzed in several studies. A recent study obtained the following correlation:

IFCC standardization (recalculated acc. to ref. 8)

- Estimated average glucose [mmol/L] = $0.146 \times \text{HbA1c (mmol/mol)} + 0.834$ or

- Estimated average glucose [mg/dL] = $2.64 \times \text{HbA1c (mmol/mol)} + 15.03$ Standardization acc. to DCCT/NGSP⁸

- Estimated average glucose [mmol/L] = $1.59 \times \text{HbA1c (%)}$ - 2.59 or
- Estimated average glucose [mg/dL] = $28.7 \times \text{HbA1c (%)}$ - 46.7

The risk of diabetic complications, such as diabetic nephropathy and retinopathy, increases with poor metabolic control. In accordance with its function as an indicator for the mean blood glucose level, HbA1c predicts the development of diabetic complications in diabetes patients.^{3,5}

For monitoring of long term glycemic control, testing every 3 to 4 months is generally sufficient. In certain clinical situations, such as gestational diabetes, or after a major change in therapy, it may be useful to measure HbA1c in 2 to 4 week intervals.⁷

Test principle^{10,11,12}

This method uses TTAB* as the detergent in the hemolyzing reagent to eliminate interference from leukocytes (TTAB does not lyse leukocytes). Sample pretreatment to remove labile HbA1c is not necessary.

All hemoglobin variants which are glycosylated at the β-chain N-terminus and which have antibody-recognizable regions identical to that of HbA1c are measured by this assay. Consequently, the metabolic state of patients having uremia or the most frequent hemoglobinopathies (HbAS, HbAC, HbAE) can be determined using this assay.^{13,14}

*TTAB = Tetradecyltrimethylammonium bromide

Hemoglobin A1c

The HbA1c determination is based on the turbidimetric inhibition immunoassay (TINIA) for hemolyzed whole blood.

- Sample and addition of R1 (Antibody reagent):
Glycohemoglobin (HbA1c) in the sample reacts with anti-HbA1c antibody to form soluble antigen-antibody complexes. Since the specific HbA1c antibody site is present only once on the HbA1c molecule, complex formation does not take place.
- Addition of R2 (Polyhapten reagent) and start of reaction:
The polyhaptens react with excess anti-HbA1c antibodies to form an insoluble antibody-polyhapten complex which can be measured turbidimetrically.

Hemoglobin

Liberated hemoglobin in the hemolyzed sample is converted to a derivative having a characteristic absorption spectrum which is measured bichromatically during the preincubation phase (sample + R1) of the above immunological reaction. A separate Hb reagent is consequently not necessary.

Ratio definition

The final result is expressed as mmol/mol HbA1c or % HbA1c and is calculated from the HbA1c/Hb ratio as follows:

Protocol 1 (% HbA1c acc. to IFCC; not recommended for patient result reporting):

$$\text{HbA1c (}\%) = (\text{HbA1c/Hb}) \times 100$$

Protocol 2 (% HbA1c acc. to DCCT/NGSP):

$$\text{HbA1c (}\%) = (\text{HbA1c/Hb}) \times 91.5 + 2.15$$

Protocol 3 (mmol/mol HbA1c acc. to IFCC):

$$\text{HbA1c (mmol/mol)} = (\text{HbA1c/Hb}) \times 1000$$

A1C-2

Tina-quant Hemoglobin A1c Gen.2



Reagents – working solutions

- R1** Antibody reagent
MES buffer: 0.025 mol/L; TRIS buffer: 0.015 mol/L, pH 6.2; HbA1c antibody (ovine serum) ≥ 0.5 mg/mL; stabilizers; preservatives (liquid)
- R2** Polyhapten reagent
MES buffer: 0.025 mol/L; TRIS buffer: 0.015 mol/L, pH 6.2; HbA1c polyhapten: ≥ 8 μ g/mL; stabilizers; preservatives (liquid)

R1 is in position B and R2 is in position C.

Precautions and warnings

For in vitro diagnostic use.
Exercise the normal precautions required for handling all laboratory reagents.
Disposal of all waste material should be in accordance with local guidelines.
Safety data sheet available for professional user on request.

Reagent handling

Ready for use

Storage and stability

A1C-2

Shelf life at 2-8 °C: See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer: 4 weeks

Hemolyzing reagent

Shelf life at 2-8 °C: See expiration date on pack label

When storing at temperatures below 3 °C, the reagent may become cloudy. This has no effect on the function of the reagent and is reversible at higher temperatures. It is therefore recommended to equilibrate the reagent at room temperature for approximately 10 minutes and mix thoroughly before use.

On-board in use and refrigerated on the analyzer: 4 weeks

Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable. Venous or capillary blood with anticoagulant. The only acceptable anticoagulants are Li-heparin, K₂-EDTA, K₃-EDTA and potassium fluoride/Na₂-EDTA.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Stability:¹⁵ 3 days at 15-25 °C
7 days at 2-8 °C
6 months at (-15)-(-25) °C

Freeze only once. Mix specimen thoroughly before use.

Hemolysate preparation for Hemolysate Application

1. Allow blood specimen and Hemolyzing Reagent for Tina-quant HbA1c to equilibrate at room temperature before use.
2. Moderately mix the sample immediately prior to pipetting to ensure a homogeneous mixture of erythrocytes. Take care to avoid the formation of foam.
3. Dilute the sample with Hemolyzing Reagent for Tina-quant HbA1c (Cat. No. 11488457 122) in the ratio 1:101 (1+100) using one of the following pipetting schemes.

Pipette into tubes:

| | | | |
|---|-------------|--------------|--------------|
| HbA1c Hemolyzing Reagent for Tina-quant HbA1c | 500 μ L | 1000 μ L | 2000 μ L |
| Specimen (patient or control) | 5 μ L | 10 μ L | 20 μ L |

4. Mix using a vibration mixer or by gentle swirling.
5. The hemolysate can be used after the solution has changed color from red to brownish-green (approx. 1-2 min).

Stability of the hemolysate:¹⁵ 4 hours at 15-25 °C
24 hours at 2-8 °C
6 months at (-15)-(-25) °C

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

- See "Order information" section
- General laboratory equipment

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

Whole Blood application for Hb (HB-W2) and HbA1c (A1-W2)

cobas c 311 test definition Hb (HB-W2)

| | |
|------------------------------|------------|
| Assay type | 1-Point |
| Reaction time / Assay points | 10 / 23 |
| Wavelength (sub/main) | 660/376 nm |
| Reaction direction | Increase |
| Unit | g/dL |

| Reagent pipetting | Diluent (H ₂ O) | |
|-------------------|----------------------------|---|
| R1 | 120 μ L | – |
| R3 | 24 μ L | – |

| Sample volumes | Sample | Sample dilution | |
|----------------|-----------|-----------------|------------------------------|
| | | Sample | Diluent (Hemolyzing reagent) |
| Normal | 5 μ L | 2 μ L | 180 μ L |
| Decreased | 5 μ L | 2 μ L | 180 μ L |
| Increased | 5 μ L | 2 μ L | 180 μ L |

cobas c 311 test definition HbA1c (A1-W2)

| | |
|------------------------------|-------------|
| Assay type | 2-Point End |
| Reaction time / Assay points | 10 / 23-57 |
| Wavelength (sub/main) | 660/340 nm |
| Reaction direction | Increase |
| Unit | g/dL |

| Reagent pipetting | Diluent (H ₂ O) | |
|-------------------|----------------------------|---|
| R1 | 120 μ L | – |
| R3 | 24 μ L | – |

A1C-2

Tina-quant Hemoglobin A1c Gen.2



| Sample volumes | Sample | Sample dilution | |
|----------------|--------|-----------------|---------------------------------|
| | | Sample | Diluent (Hemolyzing reagent) |
| Normal | 5 µL | 2 µL | 180 µL |
| Decreased | 5 µL | 2 µL | 180 µL |
| Increased | 5 µL | 2 µL | 180 µL |

cobas c 501/502 test definition Hb (HB-W2)

| | |
|------------------------------|------------|
| Assay type | 1-Point |
| Reaction time / Assay points | 10 / 34 |
| Wavelength (sub/main) | 660/376 nm |
| Reaction direction | Increase |
| Unit | g/dL |

| | | |
|-------------------|----------------------------|---|
| Reagent pipetting | Diluent (H ₂ O) | |
| R1 | 120 µL | – |
| R3 | 24 µL | – |

| Sample volumes | Sample | Sample dilution | |
|----------------|--------|-----------------|---------------------------------|
| | | Sample | Diluent (Hemolyzing reagent) |
| Normal | 5 µL | 2 µL | 180 µL |
| Decreased | 5 µL | 2 µL | 180 µL |
| Increased | 5 µL | 2 µL | 180 µL |

cobas c 501/502 test definition HbA1c (A1-W2)

| | |
|------------------------------|-------------|
| Assay type | 2-Point End |
| Reaction time / Assay points | 10 / 34-70 |
| Wavelength (sub/main) | 660/340 nm |
| Reaction direction | Increase |
| Unit | g/dL |

| | | |
|-------------------|----------------------------|---|
| Reagent pipetting | Diluent (H ₂ O) | |
| R1 | 120 µL | – |
| R3 | 24 µL | – |

| Sample volumes | Sample | Sample dilution | |
|----------------|--------|-----------------|---------------------------------|
| | | Sample | Diluent (Hemolyzing reagent) |
| Normal | 5 µL | 2 µL | 180 µL |
| Decreased | 5 µL | 2 µL | 180 µL |
| Increased | 5 µL | 2 µL | 180 µL |

Ratio definition for mmol/mol HbA1c and % HbA1c calculation

Protocol 1 (% HbA1c acc. to IFCC, not recommended for patient result reporting):

| | |
|------------------------|----------------------------|
| Abbreviated ratio name | RW12 (890) |
| Equation | $(A1-W2/HB-W2) \times 100$ |
| Unit | % |

Protocol 2 (% HbA1c acc. to DCCT/NGSP):

| | |
|------------------------|------------------------------------|
| Abbreviated ratio name | RWD2 |
| Equation | $(A1-W2/HB-W2) \times 91.5 + 2.15$ |
| Unit | % |

Protocol 1 is already implemented in the application (ACN 890). However a patient result reporting in % HbA1c (IFCC) units is not recommended. The common % HbA1c (DCCT/NGSP) units can be achieved by modifying the application according to protocol 2. The formula (ACN 890) can be modified by using the Administrator Level/EDIT Button accordingly.

Protocol 3 (mmol/mol HbA1c acc. to IFCC):

The additional mmol/mol HbA1c (IFCC) results can be automatically calculated from the analyzer by defining an additional calculated test:

| | |
|-----------------|-----------------------------|
| Sample type | Suprnt |
| Unit of Measure | mM/M |
| Report Name | HbA1c Gen.2 IFCC |
| ITEM | RWM2 |
| Formula | $(A1-W2/HB-W2) \times 1000$ |

This equation must be entered under "Utility > Calculated Test" on Roche/Hitachi **cobas c 311** and Roche/Hitachi **cobas c 501/502** analyzers.

The ratio for HbA1c (mmol/mol HbA1c acc. to IFCC and % HbA1c acc. to DCCT/NGSP) will be automatically calculated after result output of both tests.

It is recommended to report % HbA1c values to one decimal place and mmol/mol HbA1c values without decimal point, which can be entered in the editable field "expected values".

Hemolysate Application for Hb (HB-H2) and HbA1c (A1-H2)

cobas c 311 test definition Hb (HB-H2)

| | |
|------------------------------|------------|
| Assay type | 1-Point |
| Reaction time / Assay points | 10 / 23 |
| Wavelength (sub/main) | 660/376 nm |
| Reaction direction | Increase |
| Unit | g/dL |

| | | |
|-------------------|----------------------------|---|
| Reagent pipetting | Diluent (H ₂ O) | |
| R1 | 120 µL | – |
| R3 | 24 µL | – |

| Sample volumes | Sample | Sample dilution | |
|----------------|--------|-----------------|---------|
| | | Sample | Diluent |
| Normal | 5 µL | – | – |
| Decreased | 5 µL | – | – |
| Increased | 5 µL | – | – |

cobas c 311 test definition HbA1c (A1-H2)

| | |
|------------------------------|-------------|
| Assay type | 2-Point End |
| Reaction time / Assay points | 10 / 23-57 |
| Wavelength (sub/main) | 660/340 nm |
| Reaction direction | Increase |
| Unit | g/dL |

| | | |
|-------------------|----------------------------|---|
| Reagent pipetting | Diluent (H ₂ O) | |
| R1 | 120 µL | – |
| R3 | 24 µL | – |

| Sample volumes | Sample | Sample dilution | |
|----------------|--------|-----------------|---------|
| | | Sample | Diluent |

A1C-2

Tina-quant Hemoglobin A1c Gen.2



| | | | |
|-----------|------|---|---|
| Normal | 5 µL | – | – |
| Decreased | 5 µL | – | – |
| Increased | 5 µL | – | – |

cobas c 501/502 test definition Hb (HB-H2)

| | |
|------------------------------|------------|
| Assay type | 1-Point |
| Reaction time / Assay points | 10 / 34 |
| Wavelength (sub/main) | 660/376 nm |
| Reaction direction | Increase |
| Unit | g/dL |

| | | |
|-------------------|--------|----------------------------|
| Reagent pipetting | | Diluent (H ₂ O) |
| R1 | 120 µL | – |
| R3 | 24 µL | – |

| Sample volumes | Sample | Sample dilution | |
|----------------|--------|-----------------|---------|
| | | Sample | Diluent |
| Normal | 5 µL | – | – |
| Decreased | 5 µL | – | – |
| Increased | 5 µL | – | – |

cobas c 501/502 test definition HbA1c (A1-H2)

| | |
|------------------------------|-------------|
| Assay type | 2-Point End |
| Reaction time / Assay points | 10 / 34-70 |
| Wavelength (sub/main) | 660/340 nm |
| Reaction direction | Increase |
| Unit | g/dL |

| | | |
|-------------------|--------|----------------------------|
| Reagent pipetting | | Diluent (H ₂ O) |
| R1 | 120 µL | – |
| R3 | 24 µL | – |

| Sample volumes | Sample | Sample dilution | |
|----------------|--------|-----------------|---------|
| | | Sample | Diluent |
| Normal | 5 µL | – | – |
| Decreased | 5 µL | – | – |
| Increased | 5 µL | – | – |

Ratio definition for mmol/mol HbA1c and % HbA1c calculation

Protocol 1 (% HbA1c acc. to IFCC, not recommended for patient result reporting):

| | |
|------------------------|----------------------------|
| Abbreviated ratio name | RH12 (860) |
| Equation | $(A1-H2/HB-H2) \times 100$ |
| Unit | % |

Protocol 2 (% HbA1c acc. to DCCT/NGSP):

| | |
|------------------------|------------------------------------|
| Abbreviated ratio name | RHD2 |
| Equation | $(A1-H2/HB-H2) \times 91.5 + 2.15$ |
| Unit | % |

Protocol 1 is already implemented in the application (ACN 860). However a patient result reporting in % HbA1c (IFCC) units is not recommended. The common % HbA1c (DCCT/NGSP) units can be achieved by modifying the application according to protocol 2. The formula (ACN 860) can be modified by using the Administrator Level/EDIT Button accordingly.

Protocol 3 (mmol/mol HbA1c acc. to IFCC):

The additional mmol/mol HbA1c (IFCC) results can be automatically calculated from the analyzer by defining an additional calculated test:

| | |
|-----------------|-----------------------------|
| Sample type | Suprnt |
| Unit of Measure | mM/M |
| Report Name | HbA1c Gen.2 IFCC |
| ITEM | RHM2 |
| Formula | $(A1-H2/HB-H2) \times 1000$ |

This equation must be entered under "Utility > Calculated Test" on Roche/Hitachi **cobas c** 311 and Roche/Hitachi **cobas c** 501/502 analyzers.

The ratio for HbA1c (mmol/mol HbA1c acc. to IFCC and % HbA1c acc. to DCCT/NGSP) will be automatically calculated after result output of both tests.

It is recommended to report % HbA1c values to one decimal place and mmol/mol HbA1c values without decimal point, which can be entered in the editable field "expected values".

Calibration for Whole Blood and Hemolysate Application

Enter the assigned lot-specific and application-specific value of the calibrator.

Use the appropriate C.f.a.s. HbA1c calibrator only.

The **cobas c** Hemolyzing Reagent Gen.2 (51 mL; Cat. No. 04528182 190) needs to be available on the analyzer.

Otherwise the calibration cannot be performed.

Hb

| | |
|------------------|-----------------------|
| Calibrators | S1-S2: C.f.a.s. HbA1c |
| Calibration mode | Linear |

HbA1c

| | |
|-----------------------|---|
| Calibrators | S1-S6: C.f.a.s. HbA1c |
| Calibration mode | RCM |
| Calibration frequency | Hb and HbA1c: full calibration is recommended <ul style="list-style-type: none"> • after 29 days during shelf life • after reagent lot change • as required following quality control procedures Always calibrate both assays (Hb and HbA1c) in parallel. Automatic calibration at QC failure should be deactivated. |

Traceability: This method has been standardized against the approved IFCC reference method for the measurement of HbA1c in human blood^{16,17} and can be transferred to results traceable to DCCT/NGSP by calculation.

Quality control for Whole Blood and Hemolysate Application

For quality control, use control materials as listed in the "Order information" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements (**control measurement with each cassette recommended**). Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Calculation for Whole Blood and Hemolysate Application

Instrument factor

To improve the fit of the nonlinear HbA1c calibration curve, a constant and lot independent offset of 0.6 g/dL was added to all calibrator values. This offset is already included in the C.f.a.s. HbA1c calibrator target values for **cobas c** analyzers and finally needs to be subtracted from the analyzer's

A1C-2

Tina-quant Hemoglobin A1c Gen.2



results. Enter the instrument factor of the absolute HbA1c (A1-W2 or A1-H2) assay on Roche/Hitachi **cobas c** analyzers as follows:

Instrument factor for Whole Blood Application

Calibration => Status Screen => Instrument Factor => Instrument Factor Window => HbA1c (A1-W2) => a = 1.0; b = - 0.6 => update => okay

Instrument factor for Hemolysate Application

Calibration => Status Screen => Instrument Factor => Instrument Factor Window => HbA1c (A1-H2) => a = 1.0; b = - 0.6 => update => okay

Hb, HbA1c

Roche/Hitachi **cobas c** systems automatically calculate the analyte concentration of each sample.

HbA1c ratio calculation

For calculation of the mmol/mol HbA1c value (IFCC) and the % HbA1c value (DCCT/NGSP), refer to the Test principle and Ratio definition for mmol/mol HbA1c and % HbA1c calculation sections in this method sheet.

Limitations - interference for Whole Blood and Hemolysate Application^{13,14,18,19,20,21,22,23,24}

- For diagnostic purposes, mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP) should be used in conjunction with information from other diagnostic procedures and clinical evaluations.
- The test is designed only for accurate and precise measurement of mmol/mol HbA1c (IFCC) and % HbA1c (DCCT/NGSP). The individual results for total Hb and HbA1c concentration should not be reported.
- As a matter of principle, care must be taken when interpreting any HbA1c result from patients with Hb variants. Abnormal hemoglobins might affect the half life of the red cells or the in vivo glycation rates. In these cases even analytically correct results do not reflect the same level of glycemic control that would be expected in patients with normal hemoglobin.²³ Whenever it is suspected that the presence of an Hb variant (e.g. HbSS, HbCC or HbSC), affects the correlation between the HbA1c value and glycemic control, HbA1c must not be used for the diagnosis of diabetes mellitus.
- Any cause of shortened erythrocyte survival or decrease in mean erythrocyte age will reduce exposure of erythrocytes to glucose with a consequent decrease in mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP), even though the time-averaged blood glucose level may be elevated. Causes of shortened erythrocyte lifetime might be hemolytic anemia or other hemolytic diseases, homozygous sickle cell trait, pregnancy, recent significant or chronic blood loss, etc. Similarly, recent blood transfusions can alter the mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP). Caution should be used when interpreting the HbA1c results from patients with these conditions. HbA1c must not be used for the diagnosis of diabetes mellitus in the presence of such conditions.
- Glycated HbF is not detected by the assay as it does not contain the glycated β -chain that characterizes HbA1c. However, HbF is measured in the Total Hb assay and as a consequence, specimens containing high amounts of HbF (> 10 %) may result in lower than expected mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP).^{14,24}
- mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP) are not suitable for diagnosis of gestational diabetes.²⁵
- In very rare cases of rapidly evolving type 1 diabetes the increase of HbA1c values might be delayed compared to the acute increase in glucose concentrations. In these conditions diabetes mellitus must be diagnosed based on plasma glucose concentrations and/or the typical clinical symptoms.²⁵

Interference Criterion: Recovery within ± 10 % of initial value at a decision level of 42 mmol/mol HbA1c (IFCC).

Icterus:²² No significant interference up to an I index of 60 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 1026 μ mol/L or 60 mg/dL).

Lipemia (Intralipid):²² No significant interference up to an Intralipid concentration of 500 mg/dL (**cobas c** 501/502 analyzers) and 400 mg/dL (**cobas c** 311 analyzer). There is poor correlation between triglyceride concentration and turbidity.

Glycemia: No significant interference up to a glucose level of 55.5 mmol/L (1000 mg/dL). A fasting sample is not required.

Rheumatoid factors: No significant interference up to a rheumatoid factor level of 750 IU/mL.

Drugs: No interference was found at therapeutic concentrations using common drug panels.^{26,27}

Other: No cross reactions with HbA0, HbA1a, HbA1b, acetylated hemoglobin, carbamylated hemoglobin, glycated albumin and labile HbA1c were found for the anti-HbA1c antibodies used in this kit.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

ACTION REQUIRED

Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on Roche/Hitachi **cobas c** systems. The latest version of the carry-over evasion list can be found with the NaOHD-SMS-SmpCin1+2-SCCS Method Sheets. For further instructions refer to the operator's manual. **cobas c** 502 analyzer: All special wash programming necessary for avoiding carry-over is available via the **cobas** link, manual input is not required.

Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.

Limits and ranges

Measuring range

Hemoglobin: 4-35 g/dL

HbA1c: 0.3-2.5 g/dL

The technical limit in the instrument setting is defined as 0.9-3.1 g/dL due to the instrument factor for HbA1c (b = - 0.6; see above chapter *Calculation for Whole Blood and Hemolysate Application*).

This corresponds to a measuring range of 23-189 mmol/mol HbA1c at a typical hemoglobin concentration of 13.2 g/dL (IFCC values; corresponding values for DCCT/NGSP: 4.3-19.4 % HbA1c).

In rare cases of ">Test" flags which might occur with the use of the whole blood application, remix the whole blood sample and repeat the analysis with the same settings.

Lower limits of measurement

Lower detection limit of the test

Hemoglobin: 0.5 g/dL

HbA1c: 0.1 g/dL

A typical lower detection limit for the HbA1c ratio may be calculated, based on a given Hb concentration. Assuming a typical Hb concentration of 13.2 g/dL, the lower detection limit for the HbA1c ratio is 8 mmol/mol HbA1c (IFCC) or 2.9 % HbA1c (DCCT/NGSP).

The lower detection limit represents the lowest measurable analyte level that can be distinguished from 0. It is calculated as the value lying 3 standard deviations above that of the lowest standard (standard 1 + 3 SD, repeatability, n = 21).

Expected values

Protocol 1 (mmol/mol HbA1c acc. to IFCC): 29-42 mmol/mol HbA1c²⁸

Protocol 2 (% HbA1c acc. to DCCT/NGSP): 4.8-5.9 % HbA1c²⁸

This reference range was obtained by measuring 474 well-characterized healthy individuals without diabetes mellitus. HbA1c levels higher than the upper end of this reference range are an indication of hyperglycemia during the preceding 2 to 3 months or longer. According to the recommendations of the American Diabetes Association values above 48 mmol/mol HbA1c (IFCC) or 6.5 % HbA1c (DCCT/NGSP) are suitable for the diagnosis of diabetes mellitus.^{25,29} Patients with HbA1c values in the range of 39-46 mmol/mol HbA1c (IFCC) or 5.7 %-6.4 % HbA1c (DCCT/NGSP) may be at risk of developing diabetes.^{25,29}

HbA1c levels may reach 195 mmol/mol HbA1c (IFCC) or 20 % HbA1c (DCCT/NGSP) and more in poorly controlled diabetes. Therapeutic action is suggested at levels above 64 mmol/mol HbA1c (IFCC) or 8 % HbA1c (DCCT/NGSP). Diabetes patients with HbA1c levels below 53 mmol/mol HbA1c (IFCC) or 7 % HbA1c (DCCT/NGSP) meet the goal of the American Diabetes Association.^{21,20}

HbA1c levels below the established reference range may indicate recent episodes of hypoglycemia, the presence of Hb variants, or shortened lifetime of erythrocytes.

A1C-2

Tina-quant Hemoglobin A1c Gen.2



Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using human samples and controls in an internal protocol with repeatability (n = 21) and intermediate precision (3 aliquots per run, 1 run per day, 21 days). The following results were obtained (data based on DCCT/NGSP values):

Whole Blood Application:

| Repeatability | Mean | SD | CV |
|------------------------|---------|---------|-----|
| | % HbA1c | % HbA1c | % |
| Control Level 1 | 5.88 | 0.09 | 1.5 |
| Control Level 2 | 10.5 | 0.1 | 1.1 |
| Human sample 1 | 5.15 | 0.04 | 0.8 |
| Human sample 2 | 9.04 | 0.11 | 1.2 |
| Intermediate precision | Mean | SD | CV |
| | % HbA1c | % HbA1c | % |
| Control Level 1 | 6.00 | 0.12 | 1.9 |
| Control Level 2 | 10.5 | 0.2 | 2.0 |
| Human sample 3 | 5.63 | 0.07 | 1.3 |
| Human sample 4 | 11.8 | 0.2 | 1.7 |

Hemolysate Application:

| Repeatability | Mean | SD | CV |
|------------------------|---------|---------|-----|
| | % HbA1c | % HbA1c | % |
| Control Level 1 | 5.88 | 0.13 | 2.2 |
| Control Level 2 | 10.4 | 0.1 | 1.0 |
| Human sample 1 | 5.24 | 0.08 | 1.5 |
| Human sample 2 | 8.81 | 0.07 | 0.8 |
| Intermediate precision | Mean | SD | CV |
| | % HbA1c | % HbA1c | % |
| Control Level 1 | 5.95 | 0.12 | 2.0 |
| Control Level 2 | 10.1 | 0.2 | 1.6 |
| Human sample 3 | 5.61 | 0.09 | 1.6 |
| Human sample 4 | 11.7 | 0.2 | 1.5 |

Method comparison

% HbA1c values (DCCT/NGSP) for human blood samples obtained on a Roche/Hitachi **cobas c 501** analyzer (y) were compared with those determined using the corresponding reagent on a COBAS INTEGRA 800 analyzer (x) and on a Roche/Hitachi MODULAR P analyzer (x).

Whole Blood Application:

x = COBAS INTEGRA 800 analyzer, y = **cobas c 501** analyzer

Sample size (n) = 109

| | |
|------------------------------|--------------------|
| Passing/Bablok ³⁰ | Linear regression |
| y = 0.990x + 0.110 | y = 1.003x + 0.023 |
| τ = 0.958 | r = 0.996 |

The sample concentrations were between 5.04 and 12.6 % (DCCT/NGSP values).

x = Roche/Hitachi MODULAR P analyzer, y = **cobas c 501** analyzer

Sample size (n) = 93

| | |
|------------------------------|--------------------|
| Passing/Bablok ³⁰ | Linear regression |
| y = 0.984x + 0.136 | y = 0.978x + 0.196 |
| τ = 0.940 | r = 0.995 |

The sample concentrations were between 5.09 and 13.1 % (DCCT/NGSP values).

In addition, a comparison to a commercially available HPLC method was performed. The HPLC method was standardized in conformance with DCCT (Diabetes Control and Complications Trial).^{3,4}

HPLC method

Sample size (n) = 40

| | |
|------------------------------|--------------------|
| Passing/Bablok ³⁰ | Linear regression |
| y = 0.935x + 0.450 | y = 0.924x + 0.567 |
| τ = 0.950 | r = 0.993 |

The sample concentrations were between 5.25 and 11.9 % (DCCT/NGSP values).

Hemolysate Application:

x = COBAS INTEGRA 800 analyzer, y = **cobas c 501** analyzer

Sample size (n) = 109

| | |
|------------------------------|--------------------|
| Passing/Bablok ³⁰ | Linear regression |
| y = 1.032x - 0.145 | y = 1.027x - 0.108 |
| τ = 0.962 | r = 0.998 |

The sample concentrations were between 5.15 and 13.1 % (DCCT/NGSP values).

x = Roche/Hitachi MODULAR P analyzer, y = **cobas c 501** analyzer

Sample size (n) = 94

| | |
|------------------------------|--------------------|
| Passing/Bablok ³⁰ | Linear regression |
| y = 1.000x + 0.074 | y = 1.000x + 0.105 |
| τ = 0.950 | r = 0.997 |

The sample concentrations were between 5.09 and 13.1 % (DCCT/NGSP values).

In addition, a comparison to a commercially available HPLC method was performed. The HPLC method was standardized in conformance with DCCT (Diabetes Control and Complications Trial).^{3,4}

HPLC method

Sample size (n) = 40

| | |
|------------------------------|--------------------|
| Passing/Bablok ³⁰ | Linear regression |
| y = 0.949x + 0.407 | y = 0.964x + 0.328 |
| τ = 0.954 | r = 0.994 |

The sample concentrations were between 5.25 and 11.9 % (DCCT/NGSP values).

Analytical specificity

| | |
|----------------|--|
| Hb derivatives | Labile HbA1c (pre-HbA1c), acetylated Hb, and carbamylated Hb do not affect the assay results. |
| Hb variants | Specimens containing high amounts of HbF (> 10 %) may yield lower than expected HbA1c results. |

Please note

According to the consensus statement of the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and the International Diabetes Federation (IDF) HbA1c results should be reported parallel both in mmol/mol HbA1c (IFCC) and % HbA1c (DCCT/NGSP) values.³¹ In addition an HbA1c derived mean

A1C-2

Tina-quant Hemoglobin A1c Gen.2



blood glucose concentration can be reported which can be calculated according to the equations given in the Summary section of this method sheet. Former % HbA1c values (IFCC) must not be used due to the risk of mixup/misinterpretation with the % HbA1c values (DCCT/NGSP). The use of these % HbA1c values (IFCC) in this application is only an internal operand. The customer is asked to modify the application according to the consensus statement and/or local requirements.

References

- Goldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. *Diabetes Care* 1995;18:896-909.
- Goldstein DE, Little RR. More than you ever wanted to know (but need to know) about glycohemoglobin testing. *Diabetes Care* 1994;17:938-939.
- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977-986.
- Santiago JV. Lessons from the diabetes control and complications trial. *Diabetes* 1993;42:1549-1554.
- UK Prospective Diabetes Study (UKPDS) group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;352:837-853.
- Flückiger R, Mortensen HB. Review: glycated haemoglobins. *J Chromatogr* 1988;429:279-292.
- Goldstein DE, Little RR, Wiedmeyer HM, et al. Glycated hemoglobin: methodologies and clinical applications. *Clin Chem* 1986;32:B64-B70.
- Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. *Diabetes Care* 2008;31:1473-1478.
- Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. *Science* 1978;200:21-27.
- Zander R, Lang W, Wolf HU. Alkaline haematin D-575, a new tool for the determination of haemoglobin as an alternative to the cyanhaemoglobin method. I. Description of the method. *Clin Chim Acta* 1984;136:83-93.
- Wolf HU, Lang W, Zander R. Alkaline haematin D-575, a new tool for the determination of haemoglobin as an alternative to the cyanhaemoglobin method. II. Standardization of the method using pure chlorohaemin. *Clin Chim Acta* 1984;136:95-104.
- Little RR, Wiedmeyer HM, England JD, et al. Interlaboratory standardization of measurements of glycohemoglobins. *Clin Chem* 1992;38:2472-2478.
- Frank EL, Moulton L, Little RR, et al. Effects of hemoglobin C and S traits on seven glycated hemoglobin methods. *Clin Chem* 2000;46(6):864-867.
- Chang J, Hoke C, Ettinger B, et al. Evaluation and Interference Study of Hemoglobin A1c Measured by Turbidimetric Inhibition Immunoassay. *Am J Clin Pathol* 1998;109(3):274-278.
- Data on file at Roche Diagnostics.
- Kobold U, Jeppsson JO, Duelffer T, et al. Candidate reference methods for hemoglobin A1c based on peptide mapping. *Clin Chem* 1997;43:1944-1951.
- Jeppsson JO, Kobold U, Finke A, et al. Approved IFCC reference method for the measurement of HbA1c in human blood. *Clin Chem Lab Med* 2002;40:78-89.
- Martina WV, Martijn EG, van der Molen M, et al. β -N-terminal glycohemoglobins in subjects with common hemoglobinopathies: relation with fructosamine and mean erythrocyte age. *Clin Chem* 1993;39:2259-2265.
- Weykamp CW, Penders TJ, Muskiet FAJ, et al. Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. *Clin Chem* 1993;39:1717-1723.
- American Diabetes Association. Standards of Medical Care for patients with diabetes mellitus. *Diabetes Care [Suppl.]* 1995;18(1):8-15.
- Sacks BW, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. *Clin Chem* 2002;48:436-472.
- Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. *Clin Chem* 1986;32:470-475.
- Miedema K. Influence of hemoglobin variants on the determination of glycated hemoglobin. *Klin Lab* 1993;39:1029-1032.
- Rohlfing C, Connolly J, England J, et al. Effect of Elevated Fetal Hemoglobin on HbA1c Measurements: Four Common Assay Methods compared to the IFCC Reference Method. Poster Abstract AACC Annual Meeting 2006, Chicago. *Clin Chem* 2006;52(6) Suppl A 108.
- International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. *Diabetes Care* 2009;32(7):1327-1334.
- Breuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". *Eur J Clin Chem Clin Biochem* 1996;34:385-386.
- Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. *Ann Clin Biochem* 2001;38:376-385.
- Junge W, Wilke B, Halabi A, et al. Determination of reference levels in adults for hemoglobin A1c (HbA1c). Poster presentation EUROMEDLAB, Barcelona 2003.
- Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 2010;33(1):62-69.
- Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. *J Clin Chem Clin Biochem* 1988 Nov;26(11):783-790.
- Consensus statement on the worldwide standardization of the hemoglobin A1c measurement. American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine and International Diabetes Federation Consensus Committee. *Diabetes Care* 2007;30:2399-2400.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard:

| | |
|--|---------------------------------------|
| | Contents of kit |
| | Volume after reconstitution or mixing |
| | Global Trade Item Number |

COBAS, COBAS C, COBAS INTEGRA, PRECICONTROL and TINA-QUANT are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2016, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

